This study is a randomized, double-blind, sponsor-open, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-323 in healthy adult subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
82
ICON, plc.
Lenexa, Kansas, United States
Safety measured by adverse events
Time frame: Up to 8 Days in SAD Cohorts
Safety measured by adverse events
Time frame: Up to 14 Days in MAD Cohorts
Cmax of EDP-323
Time frame: Up to 5 Days in SAD Cohorts
AUC of EDP-323
Time frame: Up to 5 Days in SAD Cohorts
Cmax of EDP-323
Time frame: Up to 11 Days in MAD Cohorts
AUC of EDP-323
Time frame: Up to 11 Days in MAD Cohorts
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.